Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam for Lenalidomide-Associated Diarrhea
NCT03767257Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2018
- Primary completion
- Nov 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of colesevelam in diarrhea, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Participants With Improvement of Lenalidomide-associated Diarrhea Evaluated by CTCAE 5.0 at 4 weeks. Started Dec 2018; status: completed.
02
Drugs
colesevelam
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT03767257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767257.